• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin.

作者信息

Aljaberi Rana, Wishah Kholoud

机构信息

Department of Pediatrics, Case Western Reserve University, MetroHealth Medical Centre, Cleveland, Ohio.

Department of Allergy Immunology, Case Western Reserve University, MetroHealth Medical Centre, Cleveland, Ohio.

出版信息

Ann Allergy Asthma Immunol. 2020 Sep;125(3):349-350. doi: 10.1016/j.anai.2020.06.006. Epub 2020 Jun 4.

DOI:10.1016/j.anai.2020.06.006
PMID:32505720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7272161/
Abstract
摘要

相似文献

1
Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin.一名2019冠状病毒病患者在接受静脉注射免疫球蛋白治疗后出现阳性结果，该患者同时患有常见变异型免疫缺陷。
Ann Allergy Asthma Immunol. 2020 Sep;125(3):349-350. doi: 10.1016/j.anai.2020.06.006. Epub 2020 Jun 4.
2
The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019.一名被诊断患有2019冠状病毒病的常见可变免疫缺陷患者的临床观察。
Ann Allergy Asthma Immunol. 2020 Jul;125(1):112-114. doi: 10.1016/j.anai.2020.04.033. Epub 2020 May 5.
3
Ten things we learned about COVID-19.关于新冠病毒我们了解到的十件事。
Intensive Care Med. 2020 Aug;46(8):1590-1593. doi: 10.1007/s00134-020-06140-0. Epub 2020 Jun 5.
4
Clinical findings in a patient with haemophilia A affected by COVID-19.一名甲型血友病患者感染新型冠状病毒肺炎的临床发现。
Haemophilia. 2020 Jul;26(4):e214-e216. doi: 10.1111/hae.14000. Epub 2020 Apr 13.
5
A COVID-19 case in Libya acquired in Saudi Arabia.利比亚的一例新冠肺炎病例是在沙特阿拉伯感染的。
Travel Med Infect Dis. 2020 Sep-Oct;37:101705. doi: 10.1016/j.tmaid.2020.101705. Epub 2020 May 1.
6
SARS-CoV-2 in upper and lower airway samples of a laryngectomized patient: New insights and many lessons.喉切除患者上呼吸道和下呼吸道样本中的 SARS-CoV-2：新的认识和许多教训。
Oral Oncol. 2020 Aug;107:104841. doi: 10.1016/j.oraloncology.2020.104841. Epub 2020 Jun 4.
7
[COVID-19- what have we learned and where are we heading?].[新冠疫情——我们学到了什么，又将走向何方？]
Laeknabladid. 2020 Oct;106(10):449. doi: 10.17992/lbl.2020.10.598.
8
Dysregulated adaptive immune response contributes to severe COVID-19.适应性免疫反应失调会导致重症 COVID-19。
Cell Res. 2020 Sep;30(9):814-816. doi: 10.1038/s41422-020-0391-9. Epub 2020 Aug 5.
9
Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.一名感染新冠病毒的儿童出现高炎症综合征，经静脉注射免疫球蛋白和托珠单抗成功治愈。
Indian Pediatr. 2020 Jul 15;57(7):681-683. doi: 10.1007/s13312-020-1901-z. Epub 2020 May 10.
10
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.新冠（COVID-19）时期的思考：我们在新冠病毒致病机制、诊断、治疗及疫苗研发计划中的参与情况
Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538. Epub 2020 Apr 5.

引用本文的文献

1
Monitoring of immunoglobulin treatment compliance of patients with an inborn error of immunity during the pandemic period.大流行期间对先天性免疫缺陷患者免疫球蛋白治疗依从性的监测。
BMC Immunol. 2025 Mar 15;26(1):22. doi: 10.1186/s12865-025-00703-w.
2
Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.替沙格韦单抗-西加韦单抗在常见变异型免疫缺陷患者中的耐受性及治疗结果
J Allergy Clin Immunol Glob. 2024 Jun 13;3(3):100293. doi: 10.1016/j.jacig.2024.100293. eCollection 2024 Aug.
3
Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines.先天性免疫缺陷患者接种不同品牌和剂量的 COVID-19 疫苗后对 SARS-CoV-2 感染的临床和免疫学结局。
Tuberk Toraks. 2023 Sep;71(3):236-249. doi: 10.5578/tt.20239705.
4
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.严重急性呼吸综合征冠状病毒 2 感染和 COVID-19 对先天性免疫缺陷病患者的影响。
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
5
COMMON VARIABLE IMMUNODEFICIENCY: PREDISPOSING OR PROTECTIVE FACTOR FOR SEVERE COMPLICATIONS OF COVID-19?常见可变免疫缺陷：是 COVID-19 严重并发症的诱发因素还是保护因素？
Acta Clin Croat. 2022 Mar;61(1):107-114. doi: 10.20471/acc.2022.61.01.13.
6
COVID-19 and Inborn Errors of Immunity.COVID-19 与先天性免疫缺陷
Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9.
7
COVID-19 Infection in Patients with Humoral Immunodeficiency: A Case Series and Literature Review.体液免疫缺陷患者的新型冠状病毒肺炎感染：病例系列及文献综述
Allergy Rhinol (Providence). 2022 Apr 25;13:21526575221096044. doi: 10.1177/21526575221096044. eCollection 2022 Jan-Dec.
8
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency.在原发性抗体缺陷患者中，低IgG谷值和淋巴细胞亚群计数与COVID-19住院治疗相关。
J Allergy Clin Immunol Pract. 2022 Feb;10(2):633-636.e3. doi: 10.1016/j.jaip.2021.11.030. Epub 2021 Dec 18.
9
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.SARS-CoV-2 感染诱导的 B 细胞反应可被 BNT162b2 疫苗增强原发性抗体缺陷。
Cells. 2021 Oct 27;10(11):2915. doi: 10.3390/cells10112915.
10
Potential therapeutic approach of intravenous immunoglobulin against COVID-19.静脉注射免疫球蛋白针对新型冠状病毒肺炎的潜在治疗方法。
Allergy Asthma Clin Immunol. 2021 Oct 9;17(1):105. doi: 10.1186/s13223-021-00609-3.

本文引用的文献

1
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.大剂量静脉注射免疫球蛋白作为新型冠状病毒肺炎病情恶化患者的一种治疗选择
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
2
SARS-CoV-2: a storm is raging.新型冠状病毒：风暴正在肆虐。
J Clin Invest. 2020 May 1;130(5):2202-2205. doi: 10.1172/JCI137647.
3
COVID-19: the new challenge for rheumatologists.新型冠状病毒肺炎：风湿病学家面临的新挑战。
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180. doi: 10.55563/clinexprheumatol/r3k9l6. Epub 2020 Mar 24.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?免疫球蛋白静脉注射的免疫调节作用及 Fcγ 受体的作用：经典作用机制是否仍然适用？
Front Immunol. 2015 Jan 21;5:674. doi: 10.3389/fimmu.2014.00674. eCollection 2014.